Novartis International AG

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 versus 1.9 months with placebo * One quarter of patients in trial remained progression-free beyond ten months of treatment * RAD001 is first drug to show significant benefit after failure of initial therapy, Sutent® or Nexavar®**, with potential to address unmet medical need

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Coartem achieves high cure rates in studies[1],[2] and since 2001 has helped save an estimated 500,000 lives * Priority review by FDA underscores urgency of stopping malaria - a key goal of US President's Malaria Initiative * Working with international community, Novartis has supplied more than 195 million treatments to malaria-endemic countries without profit

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Novel vaccine produced protective immune response against broad range of representative meningococcal B strains in more than 95% of infants tested[1]

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * GALIANT[*] study in more than 2,400 patients shows Galvus as effective as commonly prescribed TZD drugs when added to metformin[1]

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Regulatory applications to be submitted worldwide for RAD001, proposed brand name Afinitor®; first submissions filed in the US, EU and Switzerland * Data showing that RAD001 more than doubles time without tumor growth and reduced risk of disease progression by 70% now published in The Lancet

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Data presented at European Society of Cardiology congress confirm Rasilez is effective in difficult-to-treat patients with obesity, heart failure and diabetes[1],[2],[3]

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * New 10mg strength offers increased treatment flexibility and more convenient dosage form